A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - CA057-001
Updated: 8 November, 2023 | ClinicalTrials.gov
Inclusion Criteria: - Participant has documented diagnosis of MM and measurable disease, defined as any of the following: - M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or - M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP) - For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio. - Participants received 1 to 3 prior lines of antimyeloma therapy. - Participants achieved minimal response [MR] or better to at least 1 prior antimyeloma therapy. Exclusion Criteria: - Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor, except as noted below: a. Subjects who progressed while being treated with, or within 60 days of last dose of bortezomib maintenance given once every 2 weeks or less are not excluded. - For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity. - Participant has had prior treatment with mezigdomide or pomalidomide. Other protocol-defined criteria apply.